Probiotic Composition with WecLac® Akkermansia muciniphila Akk11 for Hypertension Improvement

Introduction

This patent discusses a probiotic agent aimed at improving hypertension, composed primarily of the Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05. The patent identifies a synergistic effect between these strains, offering enhanced blood pressure regulation, kidney protection, and antioxidant defense, making it a promising alternative to traditional hypertension therapies.

Background

Hypertension treatments typically rely on medications such as ACE inhibitors or calcium channel blockers. However, long-term use of these can result in side effects and dependency. As a result, probiotics, known for balancing gut microbiota and offering health benefits, are increasingly being studied for their potential in managing hypertension through mechanisms such as gut-brain axis modulation and reducing oxidative stress

Key Ingredients

· Akkermansia muciniphila Akk11: Identified for its potential in modulating gut microbiota and improving hypertension.

· Lacticaseibacillus rhamnosus LRa05: A widely researched strain known for its gut health benefits, here shown to synergize with Akk11 in hypertension management.

These strains were stored under the following codes:

· Akkermansia muciniphila Akk11: CCTCC NO: M2024119

· Lacticaseibacillus rhamnosus LRa05: CGMCC NO. 24377

Mechanisms of Action

The combination of Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05 significantly improves blood pressure regulation through:

· Blood Pressure Modulation: Synergistic interaction enhances the ability to regulate blood pressure.

· Kidney Function Improvement: The strains lower urinary protein and serum creatinine levels, reducing kidney damage caused by hypertension.

· Oxidative Stress Reduction: The combination enhances the body's antioxidant defenses, reducing oxidative stress markers like malondialdehyde (MDA) while boosting antioxidant enzymes such as superoxide dismutase (SOD) and glutathione (GSH)

Formulation and Dosage

The probiotic agent can be formulated in various types, including:

· Solution,

· Freeze-dried powder,

· Capsules,

· Tablets,

· Granules.

The preparation method involves culturing the strains, separating them through centrifugation, and mixing them at specific ratios for optimal efficacy. The viable bacterial count is maintained above 1×10⁸ CFU/mL or CFU/g

Experimental Results

In animal studies using hypertensive rat models:

· Blood Pressure: The rats administered with the probiotic agent showed significantly reduced systolic blood pressure compared to the control group.

· Endocrine Response: Levels of norepinephrine and epinephrine, elevated in hypertension models, were lowered after probiotic intervention.

· Kidney Health: Both serum creatinine and urinary protein levels were significantly decreased, indicating improved kidney function.

Clinical Implications

This probiotic agent offers a non-pharmaceutical strategy for managing hypertension, particularly for individuals seeking natural alternatives. Its efficacy in reducing blood pressure and protecting kidney function positions it as a promising supplement for hypertensive patients.

Conclusion

The probiotic agent containing Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05 offers a novel approach to hypertension treatment. By leveraging the synergistic effects of these strains, it provides significant improvements in blood pressure regulation, kidney health, and oxidative stress management, presenting a viable alternative to traditional treatments